Medivir

Medivir PP&E per Employee

The PP&E per Employee of Medivir (MVIR.ST) as of Oct 29, 2026 is 1.80 M SEK. In the previous year, PP&E per Employee was 2.59 M SEK — a change of -30.37% (lower).

PP&E per Employee

1.80 MSEK

YoY

-30.37%

Last updated:

PP&E per Employee of Medivir is 2020 1.80 M SEK. PP&E per Employee of Medivir was 2019 2.59 M SEK. It decreases by -30.37% lower compared to the previous year.

The Medivir PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2014
2.99 M SEK
Jan 1, 2015
2.92 M SEK
Jan 1, 2016
2.44 M SEK
Jan 1, 2017
1.60 M SEK
Jan 1, 2018
1.20 M SEK
Jan 1, 2019
2.59 M SEK
Jan 1, 2020
1.80 M SEK
The Medivir PP&E per Employee history
YEARPP&E per EmployeeYoY
1.80 MSEK-30.37%
2.59 MSEK+115.03%
1.20 MSEK-25.00%
1.60 MSEK-34.25%
2.44 MSEK-16.46%
2.92 MSEK-2.20%
2.99 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medivir Stock analysis

What does Medivir do? Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

PP&E per Employee of Medivir is 1.80 M SEK in 2020.

PP&E per Employee of Medivir changed from 2.59 M SEK to 1.80 M SEK, representing a -30.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Medivir since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Medivir historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Medivir

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Medivir